Your browser doesn't support javascript.
loading
Urinary Nicotine Metabolites and Self-Reported Tobacco Use Among Adults in the Population Assessment of Tobacco and Health (PATH) Study, 2013-2014.
Feng, June; Sosnoff, Connie S; Bernert, John T; Blount, Benjamin C; Li, Yao; Del Valle-Pinero, Arseima Y; Kimmel, Heather L; van Bemmel, Dana M; Rutt, Sharyn M; Crespo-Barreto, Juan; Borek, Nicolette; Edwards, Kathryn C; Alexander, Ricky; Arnstein, Stephen; Lawrence, Charles; Hyland, Andrew; Goniewicz, Maciej L; Rehmani, Imran; Pine, Brittany; Pagnotti, Vincent; Wade, Erin; Sandlin, James; Luo, Zuzheng; Piyankarage, Sujeewa; Hatsukami, Dorothy K; Hecht, Stephen S; Conway, Kevin P; Wang, Lanqing.
Afiliação
  • Feng J; Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Sosnoff CS; Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Bernert JT; Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Blount BC; Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Li Y; Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Del Valle-Pinero AY; Office of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Kimmel HL; Division of Epidemiology, Services and Prevention Research, National Institute of Drug Abuse, Bethesda, MD, USA.
  • van Bemmel DM; Office of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Rutt SM; Office of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Crespo-Barreto J; Office of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Borek N; Office of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Edwards KC; Behavioral Health and Health Policy, Westat, Rockville, MD, USA.
  • Alexander R; Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Arnstein S; Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Lawrence C; Behavioral Health and Health Policy, Westat, Rockville, MD, USA.
  • Hyland A; Roswell Park Comprehensive Cancer Center, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Goniewicz ML; Roswell Park Comprehensive Cancer Center, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Rehmani I; Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Pine B; Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Pagnotti V; Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Wade E; Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Sandlin J; Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Luo Z; Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Piyankarage S; Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Hatsukami DK; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
  • Hecht SS; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
  • Conway KP; Division of Epidemiology, Services and Prevention Research, National Institute of Drug Abuse, Bethesda, MD, USA.
  • Wang L; Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Nicotine Tob Res ; 24(5): 768-777, 2022 03 26.
Article em En | MEDLINE | ID: mdl-35348786
ABSTRACT

INTRODUCTION:

The Population Assessment of Tobacco and Health (PATH) Study is a longitudinal cohort study on tobacco use behavior, attitudes and beliefs, and tobacco-related health outcomes, including biomarkers of tobacco exposure in the U.S. population. In this report we provide a summary of urinary nicotine metabolite measurements among adult users and non-users of tobacco from Wave 1 (2013-2014) of the PATH Study.

METHODS:

Total nicotine and its metabolites including cotinine, trans-3'-hydroxycotinine (HCTT), and other minor metabolites were measured in more than 11 500 adult participants by liquid chromatography tandem mass spectrometry methods. Weighted geometric means (GM) and least square means from statistical modeling were calculated for non-users and users of various tobacco products.

RESULTS:

Among daily users, the highest GM concentrations of nicotine, cotinine and HCTT were found in exclusive smokeless tobacco users, and the lowest in exclusive e-cigarette users. Exclusive combustible product users had intermediate concentrations, similar to those found in users of multiple products (polyusers). Concentrations increased with age within the categories of tobacco users, and differences associated with gender, race/ethnicity and educational attainment were also noted among user categories. Recent (past 12 months) former users had GM cotinine concentrations that were more than threefold greater than never users.

CONCLUSIONS:

These urinary nicotine metabolite data provide quantification of nicotine exposure representative of the entire US adult population during 2013-2014 and may serve as a reference for similar analyses in future measurements within this study. IMPLICATIONS Nicotine and its metabolites in urine provide perhaps the most fundamental biomarkers of recent nicotine exposure. This report, based on Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study, provides the first nationally representative data describing urinary nicotine biomarker concentrations in both non-users, and users of a variety of tobacco products including combustible, e-cigarette and smokeless products. These data provide a urinary biomarker concentration snapshot in time for the entire US population during 2013-2014, and will provide a basis for comparison with future results from continuing, periodic evaluations in the PATH Study.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistemas Eletrônicos de Liberação de Nicotina / Nicotina Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Nicotine Tob Res Assunto da revista: SAUDE PUBLICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistemas Eletrônicos de Liberação de Nicotina / Nicotina Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: Nicotine Tob Res Assunto da revista: SAUDE PUBLICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos